Harrow Q2 Revenue Beats, Reaffirms 2026 Outlook Amid Strong Product Demand
HROW sits 41% above its 52-week low of $28.54.
Summary
Harrow posted Q2 revenue of $70.7M, edging past the $70.34M consensus, driven by strong demand for VEVYE, IHEEZO, and TRIESENCE. The company reported a net loss of $0.46 per share, swinging from a profit a year ago, but maintained its full-year 2026 revenue guidance of $350M-$365M and adjusted EBITDA of $80M-$100M. The recently announced TYRVAYA acquisition is expected to contribute modestly this year, while VEVYE secured expanded formulary coverage with a top-three PBM effective August 1, supporting further market share gains. This follows the TYRVAYA deal announced just days ago, adding a new growth asset to the portfolio.
At the time of this announcement, HROW was trading at $40.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $28.54 to $54.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.